Wolverine Dr

On the record

BPC-157 TB-500 references and sources

Every quantitative claim on this site maps to an entry below. Peer-reviewed studies and FDA regulatory pages, with DOIs, PubMed IDs, and source URLs.

Back to the researchRecent studies

How to read this list

The references below are the complete citation record for this digest of BPC-157 TB-500. Entries 1–5 are the foundational constituent studies — the transected-tendon result, the VEGFR2 angiogenesis mechanism, the actin-sequestration structure, the Thymosin Beta-4 mechanism review, and the TB-500 fragment characterization. Entries 6–12 are the 2024–2026 reviews and recent animal studies. Entries 13–15 are the FDA regulatory sources behind the 503A Category 2 status and the scheduled 2026 PCAC review.

Where a study reported animal doses, those appear in the BPC-157 TB-500 dosage in the literature page as research context only. No human-use protocol is derived from any entry here.

  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  2. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. ↗
  3. Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004. ↗
  4. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012. ↗
  5. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012. ↗
  6. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. ↗
  7. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
  8. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  9. Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats. Pharmaceutics. 2025. ↗
  10. Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia-Reperfusion Injury. Medicina (Kaunas). 2025. ↗
  11. Multifunctionality and Possible Medical Application of the BPC 157 Peptide - Literature and Patent Review. Pharmaceuticals (Basel). 2025. ↗
  12. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals (Basel). 2024. ↗
  13. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (BPC-157 and 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500' entries; Category 2, effective with the September 29, 2023 update). ↗
  14. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 1 and Category 2 definitions; 503A/503B framework and bulks-list nomination process). ↗
  15. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (BPC-157 and TB-500 listed as substances 'being considered for inclusion on the 503A Bulks List'; scheduled discussion, not a decision). ↗